Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Conatus Pharmaceuticals has dosed the first patient in a Phase 2b clinical trial evaluating CTS-1027 in combination with Peginterferon Alfa-2a (Pegasys) and ribavirin (Copegus) in hepatitis C (HCV) null responder patient population.
Subscribe to our email newsletter
CTS-1027 is an oral, small molecule compound that inhibits the activity of key members of a class of protease enzymes, the matrix metalloproteinases (MMPs).
The trial will evaluate the safety, tolerability, and antiviral activity of the triple combination after up to 48 weeks of therapy.
The trial will also assess if higher dose levels of CTS-1027 will improve on previously observed results.
The placebo-controlled, multicentre, double-blind, randomised trial will enroll approximately 260 patients who will receive Peginterferon Alfa-2a (Pegasys) and ribavirin (Copegus) with or without CTS-1027.
The trial will be conducted at up to 50 medical centres across the US.